PANTOGAR

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT PANTOGAR (PANTOGAR®)

Composition:

Active ingredients: medical yeast, calcium pantothenate, thiamine nitrate, cystine, keratin, 4-aminobenzoic acid;

1 capsule contains: medical yeast 100 mg; calcium pantothenate 60 mg; thiamine nitrate 60 mg; cystine 20 mg; keratin 20 mg; 4-aminobenzoic acid 20 mg;

Excipients: microcrystalline cellulose, povidone, colloidal anhydrous silicon dioxide, talc, magnesium stearate, gelatin, titanium dioxide (E 171), iron oxide yellow (E 172), indigotine (E 132).

Pharmaceutical form. Capsules.

Main physicochemical properties: hard gelatin capsules size 1 with dark green opaque cap and ivory-colored opaque body; capsule contents – fine beige-brown powder with a faint yeast odor.

Pharmaco-therapeutic group. Combined vitamin preparations. ATC code: A11JC.

Pharmacological Properties

Pharmacodynamics

The active ingredients of the drug belong to the following therapeutic groups: vitamins, dietary supplements, amino acids, proteins.

Thiamine nitrate, calcium pantothenate, and other vitamins present in nutritional yeast are essential for maintaining optimal regulation of metabolism in the body.

Insufficient intake of these vitamins by the body leads to deficiency symptoms.

Keratin is the main component of hair and nails; cystine and 4-aminobenzoic acid are also substances that strengthen hair and nails.

Pantogar reduces hair loss caused by various factors, improves hair structure, and increases its resistance to mechanical and chemical damage. Pantogar promotes nail growth and enhances their strength.

Pharmacokinetics

Pharmacokinetic studies of Pantogar have not been conducted. Vitamins are absorbed in the upper gastrointestinal tract. Amino acid components derived from keratin hydrolysis (L-cystine and 4-aminobenzoic acid) are absorbed via passive diffusion and/or specific transport systems.

Clinical characteristics.

Indications.

Diffuse hair loss (hair loss of unknown origin).

Degenerative changes in hair structure (thin, coarse, brittle, lifeless, dull, colorless hair).

Hair damaged by sunlight or UV radiation.

Prevention of premature graying.

Nail growth disorders (brittleness, splitting, inflexibility).

Contraindications.

Hypersensitivity to any component of the product.

Interaction with other medicinal products and other forms of interaction.

When used concomitantly with drugs containing sulfonamides, consult a physician.

Special precautions for use.

Use during pregnancy or breastfeeding.

Animal studies are insufficient to determine effects on pregnancy, embryo/fetal development, offspring development, and postnatal development. Risk to humans is unknown. PANTOGAR should be prescribed during pregnancy and lactation only after careful assessment of the benefit and potential risk.

Ability to influence reaction rate when driving vehicles or operating machinery.

No influence.

Method of Administration and Dosage.

For oral use.

The medication should be taken during meals, without chewing, and with sufficient amount of liquid.

Adults should take 1 capsule three times a day; children aged 12 years and older – 1–2 capsules once daily.

The average duration of treatment is 3–6 months. If necessary, the treatment course may be prolonged or repeated.

Children.

Due to insufficient experience of use in younger children, the medication should not be administered to children under 12 years of age.

Overdose.

Symptoms of overdose are unknown.

Side effects

The adverse reactions listed below are classified by organ systems and frequency of occurrence. Frequency categories: very common ≥ 1/10, common ≥ 1/100 and < 1/10, uncommon ≥ 1/1000 and < 1/100, rare ≥ 1/10,000 and < 1/1000, very rare < 1/10,000, or frequency not known if the frequency cannot be estimated from available data.

Nervous system disorders

Frequency not known: headache, dizziness.

Cardiovascular system disorders

Rare: tachycardia, accelerated pulse.

Frequency not known: rapid heartbeat (palpitations).

Gastrointestinal disorders

Frequency not known: nausea, vomiting, abdominal pain, flatulence, heartburn, diarrhea.

Skin and appendages disorders

Rare: urticaria, rash, pruritus.

Frequency not known: skin redness.

Immune system disorders

Rare: hypersensitivity reactions such as increased sweating.

If any adverse reactions occur, discontinue use of the medicinal product and consult a physician.

Shelf life. 3 years.

Do not use after the expiry date stated on the packaging.

Storage conditions.

Store at temperatures not exceeding 25 °C. Keep out of reach and sight of children.

Packaging.

15 capsules in a blister pack, 6 blisters in a cardboard box.

Classification of supply.

Over-the-counter (without prescription).

Manufacturer.

Asino Pharma AG / Acino Pharma AG.

Manufacturer's address and location of operations.

Birsweg 2, 4253 Liesberg, Switzerland / Birsweg 2, 4253 Liesberg, Switzerland.